Katarzyna M Lamperska1, Piotr Kozlowski2, Tomasz Kolenda1,3, Anna Teresiak1, Renata Blizniak1, Weronika Przybyla1, Michal M Masternak4, Pawel Golusinski5, Wojciech Golusinski5. 1. Laboratory of Cancer Genetics, Greater Poland Cancer Center, Poznan, Poland. 2. European Center of Bioinformatics and Genomics (ECBaG), Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland. 3. Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland. 4. Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA. 5. Department of Head and Neck Surgery, Greater Poland Cancer Center, Poznan, Poland.
Abstract
BACKGROUND: The necessity of prediction and treatment outcome improvement of HNSCC needs to find new biomarkers. miRNAs seem to be good candidate for that. OBJECTIVE: Analysis of selected 5 miRNAs (let-7d, miR-18a, miR-21, miR-205 and miR-375) as potential biomarkers that allows to distinguish tumor and healthy tissue taken from HNSCC patients. METHODS: Tumor and normal epithelial tissues were obtained from 75 HNSCC patients to analyze selected miRNAs. RESULTS: Analysis indicated significant increase of miR-21 and miR-205 in tumor when compared with healthy tissue (p= 0.0069 and p= 0.0029, respectively). There was a significant correlation between let-7d and miR-18a. let-7d was down-regulated in 34.67% cases, miR-18a in 29.33%, miR-21 in 20%, miR-205 in 30.67% and miR-375 in 52% cases. At the same time over-expression of let-7d was detected in 18.67% cases, miR-18a in 22.67%, miR-21 in 48%, miR-205 in 41.33% and miR-375 in 52% cases. There was no correlation between miRNA expression and clinical data and the course of illness. CONCLUSION: Our study indicated that miR-21 and miR-205 can be used to analyze the clarity of surgical margins and that concomitant changes in the expression of let-7 and miR-18a in tumor tissues might represent important future markers indicating the biology of HNSCC. These observations will help with developing personalization for HNSCC patients' treatment.
BACKGROUND: The necessity of prediction and treatment outcome improvement of HNSCC needs to find new biomarkers. miRNAs seem to be good candidate for that. OBJECTIVE: Analysis of selected 5 miRNAs (let-7d, miR-18a, miR-21, miR-205 and miR-375) as potential biomarkers that allows to distinguish tumor and healthy tissue taken from HNSCC patients. METHODS:Tumor and normal epithelial tissues were obtained from 75 HNSCC patients to analyze selected miRNAs. RESULTS: Analysis indicated significant increase of miR-21 and miR-205 in tumor when compared with healthy tissue (p= 0.0069 and p= 0.0029, respectively). There was a significant correlation between let-7d and miR-18a. let-7d was down-regulated in 34.67% cases, miR-18a in 29.33%, miR-21 in 20%, miR-205 in 30.67% and miR-375 in 52% cases. At the same time over-expression of let-7d was detected in 18.67% cases, miR-18a in 22.67%, miR-21 in 48%, miR-205 in 41.33% and miR-375 in 52% cases. There was no correlation between miRNA expression and clinical data and the course of illness. CONCLUSION: Our study indicated that miR-21 and miR-205 can be used to analyze the clarity of surgical margins and that concomitant changes in the expression of let-7 and miR-18a in tumor tissues might represent important future markers indicating the biology of HNSCC. These observations will help with developing personalization for HNSCC patients' treatment.
Authors: Jixi Li; Kang Liu; Tingting Zhang; Zhendong Yang; Rensheng Wang; Gang Chen; Min Kang Journal: Am J Transl Res Date: 2018-08-15 Impact factor: 4.060
Authors: Tomasz Kolenda; Kacper Guglas; Marcel Ryś; Marta Bogaczyńska; Anna Teresiak; Renata Bliźniak; Izabela Łasińska; Jacek Mackiewicz; Katarzyna M Lamperska Journal: Rep Pract Oncol Radiother Date: 2017-08-01
Authors: Tomasz Kolenda; Weronika Przybyła; Marta Kapałczyńska; Anna Teresiak; Maria Zajączkowska; Renata Bliźniak; Katarzyna M Lamperska Journal: Rep Pract Oncol Radiother Date: 2018-03-17
Authors: Katarzyna Monika Lamperska; Tomasz Kolenda; Anna Teresiak; Anna Kowalik; Marta Kruszyna-Mochalska; Weronika Jackowiak; Renata Bliźniak; Weronika Przybyła; Marta Kapałczyńska; Piotr Kozlowski Journal: PLoS One Date: 2017-06-30 Impact factor: 3.240
Authors: Lidia Maria Rebolho Batista Arantes; Ana Carolina Laus; Matias Eliseo Melendez; Ana Carolina de Carvalho; Bruna Pereira Sorroche; Pedro Rafael Martins De Marchi; Adriane Feijó Evangelista; Cristovam Scapulatempo-Neto; Luciano de Souza Viana; André Lopes Carvalho Journal: Oncotarget Date: 2017-02-07
Authors: Kacper Guglas; Marta Bogaczyńska; Tomasz Kolenda; Marcel Ryś; Anna Teresiak; Renata Bliźniak; Izabela Łasińska; Jacek Mackiewicz; Katarzyna Lamperska Journal: Contemp Oncol (Pozn) Date: 2017-12-30